Using multi-omic analysis, plus our proprietary AI vaccine model, we will design personalized vaccines for each cancer type, and combine drugs proven for each cancer type, reaching for a pan cancer approach
The Future: All Solid Cancers
Solid tumors
Colorectal cancer (MSS)
Lung cancer
Breast cancer
Melanoma
Pancreatic cancer
AI platform
✔
✔
✔
✔
✔
Choose drugs to improve TME
✔
✔
✔
✔
Write IND
✔
✔
IND approved
✔
2024
Clinical trial start
2024
Colorectal cancer
2nd most common cause of cancer death
Without a complete surgical resection, most therapies are not curative
BreakBio's approach aims for a curative therapy
CRC often has a low Tumor Mutational Burden (TMB), BreakBio's vaccine finds viable targets even in low TMB cancer types
BreakBio is aiming for Breakthrough Therapy Designation for CRC
Lung cancer
Leading cause of cancer death
Most patients are diagnosed at stage IV, past the point of operability
High five year recurrence rate post-surgical resection even in early stages
Several common mutations in lung cancer which produce highly immunogenic peptides
